Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
Exact Sciences Corp a un objectif de cours consensus de $68.62, basé sur les évaluations des 28 analystes. Le plus élevé est de $90 attribué par Bernstein le octobre 30, 2024, et le plus bas est de $46 attribué par RBC Capital le août 7, 2025. Les 3 dernières évaluations d'analystes ont été publiées par BTIG, Piper Sandler et Evercore ISI Group le août 12, 2025, août 11, 2025 et août 8, 2025. Avec un objectif de cours moyen de $61.33 entre BTIG, Piper Sandler et Evercore ISI Group, il y a une variation implicite de 31.63% upside pour Exact Sciences Corp à partir de ces dernières évaluations d'analystes.
Sociétés d'analyse émettant des recommandations1
BTIG
Piper Sandler
Evercore ISI Group
UBS
RBC Capital
1calculé à partir des notes des analystes
Notes d'analystes pour Exact Sciences
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
08/12/2025 | 28.77% | BTIG | $65 → $60 | Maintains | Buy | |||
08/11/2025 | 28.77% | Piper Sandler | $70 → $60 | Maintains | Overweight | |||
08/08/2025 | 37.35% | Evercore ISI Group | $68 → $64 | Maintains | Outperform | |||
08/07/2025 | 13.75% | UBS | $61 → $53 | Maintains | Neutral | |||
08/07/2025 | -1.28% | RBC Capital | $54 → $46 | Maintains | Sector Perform | |||
08/07/2025 | 18.04% | Barclays | $65 → $55 | Maintains | Overweight | |||
07/08/2025 | 45.94% | Evercore ISI Group | $66 → $68 | Maintains | Outperform | |||
06/24/2025 | 39.5% | Barclays | $75 → $65 | Maintains | Overweight | |||
05/02/2025 | 60.96% | Barclays | $55 → $75 | Maintains | Overweight | |||
05/02/2025 | 15.89% | RBC Capital | $52 → $54 | Maintains | Sector Perform | |||
05/02/2025 | 41.65% | Evercore ISI Group | $60 → $66 | Maintains | Outperform | |||
05/02/2025 | 54.52% | Baird | $69 → $72 | Maintains | Outperform | |||
04/11/2025 | 28.77% | Guggenheim | $60 → $60 | Reiterates | Buy → Buy | |||
04/10/2025 | 18.04% | Barclays | $65 → $55 | Maintains | Overweight | |||
04/10/2025 | 28.77% | Mizuho | → $60 | Initiates | → Outperform | |||
03/13/2025 | 11.6% | RBC Capital | → $52 | Initiates | → Sector Perform | |||
02/26/2025 | 50.23% | Piper Sandler | $75 → $70 | Maintains | Overweight | |||
02/24/2025 | 56.67% | Scotiabank | $70 → $73 | Maintains | Sector Outperform | |||
02/20/2025 | 39.5% | B of A Securities | $72 → $65 | Maintains | Buy | |||
02/20/2025 | 39.5% | Barclays | $70 → $65 | Maintains | Overweight | |||
01/23/2025 | 50.23% | Barclays | → $70 | Initiates | → Overweight | |||
01/13/2025 | 39.5% | Benchmark | $65 → $65 | Reiterates | Buy → Buy | |||
12/13/2024 | 54.52% | B of A Securities | $75 → $72 | Maintains | Buy | |||
11/26/2024 | 84.57% | TD Cowen | $82 → $86 | Maintains | Buy | |||
11/26/2024 | 60.96% | BTIG | $65 → $75 | Maintains | Buy | |||
11/11/2024 | 60.96% | Piper Sandler | $85 → $75 | Maintains | Overweight | |||
11/06/2024 | 60.96% | Citigroup | $80 → $75 | Maintains | Buy | |||
11/06/2024 | 82.42% | Jefferies | $84 → $85 | Maintains | Buy | |||
11/06/2024 | 39.5% | BTIG | $82 → $65 | Maintains | Buy | |||
11/06/2024 | 43.79% | Stifel | $82 → $67 | Maintains | Buy | |||
11/06/2024 | 60.96% | Canaccord Genuity | $95 → $75 | Maintains | Buy | |||
11/06/2024 | 75.98% | TD Cowen | $90 → $82 | Maintains | Buy | |||
11/06/2024 | 39.5% | Goldman Sachs | $75 → $65 | Maintains | Buy | |||
11/06/2024 | 28.77% | Evercore ISI Group | $80 → $60 | Maintains | Outperform | |||
11/06/2024 | 39.5% | Craig-Hallum | $82 → $65 | Maintains | Buy | |||
11/06/2024 | 39.5% | Benchmark | $67 → $65 | Maintains | Buy | |||
11/06/2024 | 43.79% | Baird | $70 → $67 | Maintains | Outperform | |||
10/30/2024 | 93.15% | Bernstein | $75 → $90 | Maintains | Outperform | |||
10/29/2024 | 103.88% | Canaccord Genuity | $75 → $95 | Maintains | Buy | |||
10/01/2024 | 71.69% | Evercore ISI Group | $72 → $80 | Maintains | Outperform | |||
09/26/2024 | — | Raymond James | — | Reiterates | → Market Perform | |||
09/13/2024 | 60.96% | Canaccord Genuity | $75 → $75 | Maintains | Buy | |||
09/12/2024 | 82.42% | Piper Sandler | $75 → $85 | Maintains | Overweight | |||
08/27/2024 | 60.96% | Wells Fargo | → $75 | Initiates | → Overweight | |||
08/01/2024 | 43.79% | Benchmark | $91 → $67 | Maintains | Buy | |||
08/01/2024 | 75.98% | Stifel | $100 → $82 | Maintains | Buy | |||
07/17/2024 | 60.96% | Goldman Sachs | $88 → $75 | Maintains | Buy | |||
07/02/2024 | 54.52% | Evercore ISI Group | $80 → $72 | Maintains | Outperform | |||
06/27/2024 | 50.23% | BTIG | $80 → $70 | Maintains | Buy | |||
06/27/2024 | 50.23% | Scotiabank | → $70 | Initiates | → Sector Outperform | |||
06/26/2024 | 50.23% | BTIG | $80 → $70 | Maintains | Buy | |||
05/09/2024 | 71.69% | BTIG | $85 → $80 | Maintains | Buy | |||
05/09/2024 | 82.42% | Canaccord Genuity | $90 → $85 | Maintains | Buy | |||
05/09/2024 | 71.69% | Citigroup | $100 → $80 | Maintains | Buy | |||
04/03/2024 | 114.62% | Citigroup | → $100 | Maintains | Buy | |||
02/22/2024 | 93.15% | Canaccord Genuity | $100 → $90 | Maintains | Buy | |||
01/02/2024 | 95.3% | Benchmark | → $91 | Upgrade | Hold → Buy | |||
12/14/2023 | 93.15% | Guggenheim | → $90 | Initiates | → Buy | |||
12/13/2023 | — | Wolfe Research | — | Initiates | → Outperform | |||
11/03/2023 | 93.15% | Goldman Sachs | $100 → $90 | Maintains | Buy | |||
10/16/2023 | 71.69% | Piper Sandler | $90 → $80 | Maintains | Overweight | |||
10/10/2023 | 93.15% | Piper Sandler | → $90 | Upgrade | Neutral → Overweight | |||
09/28/2023 | 78.13% | Bernstein | → $83 | Initiates | → Outperform | |||
08/08/2023 | 93.15% | Piper Sandler | $80 → $90 | Maintains | Neutral | |||
08/03/2023 | 136.08% | Jefferies | $100 → $110 | Maintains | Buy | |||
08/02/2023 | 93.15% | Credit Suisse | $75 → $90 | Maintains | Neutral | |||
08/02/2023 | 159.68% | Baird | $99 → $121 | Maintains | Outperform | |||
08/02/2023 | — | Benchmark | — | Downgrade | Buy → Hold | |||
07/24/2023 | 136.08% | Goldman Sachs | $85 → $110 | Maintains | Buy | |||
07/21/2023 | 136.08% | Goldman Sachs | $85 → $110 | Maintains | Buy | |||
06/23/2023 | 146.81% | Canaccord Genuity | $92 → $115 | Maintains | Buy | |||
06/22/2023 | 179% | Citigroup | $100 → $130 | Maintains | Buy | |||
06/22/2023 | 106.03% | Benchmark | → $96 | Reiterates | Buy → Buy | |||
06/21/2023 | 82.42% | Stifel | → $85 | Reiterates | Buy → Buy | |||
06/21/2023 | 97.45% | Canaccord Genuity | → $92 | Reiterates | Buy → Buy | |||
06/07/2023 | 114.62% | Jefferies | $82 → $100 | Maintains | Buy | |||
05/11/2023 | 114.62% | Citigroup | $90 → $100 | Maintains | Buy | |||
05/10/2023 | 75.98% | Jefferies | $72 → $82 | Maintains | Buy | |||
05/10/2023 | 88.86% | B of A Securities | $80 → $88 | Maintains | Buy | |||
05/10/2023 | 60.96% | Credit Suisse | $70 → $75 | Maintains | Neutral | |||
05/10/2023 | 112.47% | Baird | $92 → $99 | Maintains | Outperform | |||
05/10/2023 | 82.42% | Craig-Hallum | $55 → $85 | Upgrade | Hold → Buy | |||
05/05/2023 | 56.67% | UBS | → $73 | Initiates | → Neutral | |||
03/15/2023 | 67.4% | Benchmark | $54 → $78 | Maintains | Buy | |||
03/09/2023 | 93.15% | Citigroup | $70 → $90 | Upgrade | Neutral → Buy | |||
03/03/2023 | 50.23% | Piper Sandler | $50 → $70 | Maintains | Neutral | |||
02/22/2023 | 63.11% | Cowen & Co. | $56 → $76 | Maintains | Outperform | |||
02/22/2023 | 97.45% | Baird | $89 → $92 | Maintains | Outperform | |||
02/22/2023 | 71.69% | BTIG | $85 → $80 | Maintains | Buy | |||
02/22/2023 | 60.96% | Canaccord Genuity | $70 → $75 | Maintains | Buy | |||
02/22/2023 | 50.23% | Citigroup | $35 → $70 | Maintains | Neutral | |||
02/22/2023 | 50.23% | Credit Suisse | → $70 | Reiterates | → Neutral | |||
02/10/2023 | 50.23% | Credit Suisse | $50 → $70 | Downgrade | Outperform → Neutral | |||
01/18/2023 | — | Raymond James | — | Downgrade | Outperform → Market Perform | |||
01/12/2023 | 60.96% | SVB Leerink | $70 → $75 | Maintains | Outperform | |||
01/06/2023 | 50.23% | SVB Leerink | $60 → $70 | Maintains | Outperform | |||
12/16/2022 | 50.23% | Jefferies | → $70 | Maintains | Buy | |||
11/14/2022 | 7.31% | Piper Sandler | $40 → $50 | Maintains | Neutral | |||
11/08/2022 | 28.77% | Raymond James | $70 → $60 | Maintains | Outperform | |||
11/07/2022 | 39.5% | BTIG | $70 → $65 | Maintains | Buy |
FAQ
Quel est le cours indicatif de l'action Exact Sciences (EXAS) ?
Le dernier objectif de prix pour Exact Sciences (NASDAQ:EXAS) a été rapporté par BTIG le août 12, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $60.00 s'attendant à ce que EXAS se rise dans les 12 prochains mois (un possible changement de 31.98% upside). 44 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour Exact Sciences (EXAS) ?
La dernière note d'analyste pour Exact Sciences (NASDAQ:EXAS) a été fournie par BTIG, et Exact Sciences maintenu leur note buy.
Quand a eu lieu la dernière mise à niveau pour Exact Sciences (EXAS) ?
La dernière amélioration pour Exact Sciences Corp a eu lieu le janvier 2, 2024 lorsque Benchmark a augmenté leur objectif de prix à $91. Benchmark avait précédemment a hold pour Exact Sciences Corp.
Quand a eu lieu la dernière dégradation pour Exact Sciences (EXAS) ?
La dernière réduction pour Exact Sciences Corp a eu lieu le août 2, 2023 lorsque Benchmark a changé leur objectif de prix de N/A à N/A pour Exact Sciences Corp.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour Exact Sciences (EXAS) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de Exact Sciences, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour Exact Sciences a été déposée le août 12, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers août 12, 2026.
La note d'analyste pour Exact Sciences (EXAS) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de Exact Sciences (EXAS) était un maintenu avec un objectif de prix de $65.00 à $60.00. Le prix actuel de Exact Sciences (EXAS) est de $45.46, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.